Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
Danaher Corp. pages available for free this week:
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Long-term (Investment) Activity Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Dividend Discount Model (DDM)
- Operating Profit Margin since 2005
- Price to Operating Profit (P/OP) since 2005
- Analysis of Revenues
- Analysis of Debt
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Danaher Corp. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Current ratio | ||||||
Quick ratio | ||||||
Cash ratio |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
The analysis of liquidity ratios over the five-year period reveals notable fluctuations, indicating varying degrees of short-term financial stability.
- Current Ratio
- The current ratio starts at a relatively strong level of 1.86 in 2020, declines to 1.43 in 2021, then rebounds to a peak of 1.89 in 2022. Subsequent years show a decreasing trend to 1.68 in 2023 and further down to 1.4 by 2024. This pattern suggests intermittent changes in current assets relative to current liabilities, with a downward shift toward the later years, potentially pointing to a tightening liquidity position.
- Quick Ratio
- The quick ratio exhibits a more pronounced downward trend overall. Beginning at 1.36 in 2020, it drops sharply to 0.89 in 2021, recovers partially to 1.3 in 2022, and then declines successively to 1.18 in 2023 and 0.83 in 2024. This indicates a reduction in the most liquid assets excluding inventory when compared to current liabilities, particularly concerning in the most recent year.
- Cash Ratio
- The cash ratio shows the most significant volatility and decline. From a moderate 0.82 in 2020, the ratio falls dramatically to 0.32 in 2021, climbs back to 0.71 in both 2022 and 2023, before dropping again to 0.31 in 2024. This fluctuation highlights inconsistencies in the company’s immediately available cash and cash equivalents relative to current liabilities, with the lowest points observed in 2021 and 2024, suggesting periods of constrained liquidity.
Overall, these liquidity indicators reflect variability in the company's ability to cover short-term obligations, with a concerning trend towards lower liquidity ratios in the most recent year. The simultaneous declines in quick and cash ratios in 2024 underscore potential challenges in maintaining readily accessible assets, which may warrant strategic liquidity management.
Current Ratio
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Current assets | ||||||
Current liabilities | ||||||
Liquidity Ratio | ||||||
Current ratio1 | ||||||
Benchmarks | ||||||
Current Ratio, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Current Ratio, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Current Ratio, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
- Current Assets
- The value of current assets exhibited fluctuations over the observed period. It decreased from approximately 13,802 million US dollars at the end of 2020 to 11,648 million in 2021, followed by a significant increase to 15,883 million in 2022. After this peak, current assets declined again to 13,937 million in 2023 and further to 9,497 million in 2024, indicating variability with an overall downward trend in the last two years.
- Current Liabilities
- Current liabilities showed a generally increasing trend from 7,402 million US dollars in 2020 to a peak of 8,389 million in 2022. Following this peak, there was a slight decline to 8,274 million in 2023, and a more pronounced reduction to 6,798 million in 2024. These figures suggest that the company managed to reduce its short-term obligations towards the end of the period analyzed.
- Current Ratio
- The current ratio, a measure of short-term liquidity, reflected fluctuations similar to those seen in current assets and liabilities. Starting at a strong ratio of 1.86 in 2020, it fell to 1.43 in 2021, then rebounded to its highest level of 1.89 in 2022. In the subsequent years, the ratio declined to 1.68 in 2023 and further to 1.4 in 2024. This downward trend in recent years suggests a weakening in the company's short-term liquidity position despite some recovery in earlier years.
Quick Ratio
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Cash and equivalents | ||||||
Trade accounts receivable, less allowance for doubtful accounts | ||||||
Total quick assets | ||||||
Current liabilities | ||||||
Liquidity Ratio | ||||||
Quick ratio1 | ||||||
Benchmarks | ||||||
Quick Ratio, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Quick Ratio, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Quick Ratio, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The financial data reveals notable fluctuations in liquidity over the analyzed periods.
- Total Quick Assets
- There is a significant decrease from US$10,080 million in 2020 to US$7,217 million in 2021. This is followed by an increase to US$10,913 million in 2022, suggesting recovery or accumulation of liquid assets during that year. However, the subsequent years show a downward trend, with figures falling to US$9,786 million in 2023 and further declining sharply to US$5,615 million in 2024.
- Current Liabilities
- The current liabilities exhibit a gradual increase from US$7,402 million in 2020 to a peak of US$8,389 million in 2022. This level remains relatively stable into 2023 at US$8,274 million before decreasing to US$6,798 million in 2024, indicating a reduction in short-term obligations at the end of the period.
- Quick Ratio
- The quick ratio mirrors the movements in quick assets relative to current liabilities. It declines from 1.36 in 2020 to 0.89 in 2021, reflecting weakened liquidity. Recovery is noted in 2022 with a rise to 1.30, followed by a slight decrease to 1.18 in 2023. By 2024, the ratio falls below 1.0 to 0.83, which may indicate that quick assets are insufficient to cover current liabilities, potentially signaling liquidity concerns.
Overall, the trends indicate periods of liquidity stress, particularly in 2021 and 2024, while 2022 shows a temporary improvement. The declining quick ratio in the latest year suggests the company may face challenges meeting short-term liabilities solely with its most liquid assets. Monitoring these ratios in upcoming periods will be critical for assessing liquidity risk and financial stability.
Cash Ratio
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Cash and equivalents | ||||||
Total cash assets | ||||||
Current liabilities | ||||||
Liquidity Ratio | ||||||
Cash ratio1 | ||||||
Benchmarks | ||||||
Cash Ratio, Competitors2 | ||||||
AbbVie Inc. | ||||||
Amgen Inc. | ||||||
Bristol-Myers Squibb Co. | ||||||
Eli Lilly & Co. | ||||||
Gilead Sciences Inc. | ||||||
Johnson & Johnson | ||||||
Merck & Co. Inc. | ||||||
Pfizer Inc. | ||||||
Regeneron Pharmaceuticals Inc. | ||||||
Thermo Fisher Scientific Inc. | ||||||
Vertex Pharmaceuticals Inc. | ||||||
Cash Ratio, Sector | ||||||
Pharmaceuticals, Biotechnology & Life Sciences | ||||||
Cash Ratio, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The financial data reveals several notable trends over the five-year period from December 31, 2020, to December 31, 2024.
- Total Cash Assets
- The total cash assets demonstrate a fluctuating pattern. Beginning at 6,035 million US dollars in 2020, cash assets experienced a significant decline to 2,586 million in 2021. This was followed by a sharp recovery to 5,995 million in 2022, remaining relatively stable in 2023 at 5,864 million before declining again to 2,078 million in 2024. Overall, cash assets exhibit volatility with notable peaks in 2020 and 2022-2023, contrasted by lower levels in 2021 and 2024.
- Current Liabilities
- Current liabilities show a generally increasing trend from 7,402 million in 2020 to a peak of 8,389 million in 2022. In 2023, there is a slight decrease to 8,274 million, followed by a more pronounced reduction in 2024 to 6,798 million. Despite the reductions in the most recent year, current liabilities have overall remained relatively high compared to the initial 2020 level, except for the drop in 2024.
- Cash Ratio
- The cash ratio, which measures the ability to cover current liabilities with cash assets, declined sharply from 0.82 in 2020 to a low of 0.32 in 2021. It improved considerably to 0.71 in both 2022 and 2023, reflecting better liquidity during those years. However, the ratio fell again to 0.31 in 2024, indicating a reduced capacity to cover current liabilities with available cash. This fluctuating pattern correlates closely with the trends seen in total cash assets and current liabilities.
In summary, the data indicates volatility in the company's cash assets and liquidity position over the observed period. While current liabilities trended upwards initially, they declined in the most recent year. The cash ratio’s decline in 2021 and 2024 suggests periods of constrained liquidity, contrasting with improved liquidity in 2022 and 2023. These patterns suggest the need for monitoring cash management practices and working capital efficiency going forward.